101 College Street
Come learn about the stages of drug development from someone who has seen it all. As a contract development and manufacturing organization (CDMO) with its own innovation pipeline, Therapure Biopharma has a unique perspective on growing a business in the life sciences industry. David Bell, VP Drug Development & CSO, will share his experiences in drug development at Therapure, with lessons for researchers and entrepreneurs alike.
Part of the MaRS Future of Medicine™ Series
David's primary responsibility at Therapure has been the development of a pipeline of new protein and cell culture based product candidates for the treatment of anemia, cancer and infectious diseases. He also leads the team offering development services for new product entries. Prior to joining the company in 1994, David was Group Leader of Cancer Biology at BioChem Therapeutic, Inc. and before this, Laboratory Director of the BioVentures Division of FAA in Worcester, Massachussetts, USA. He received his Ph.D. from the Department of Medicine of McGill University in 1988 and completed a postdoctoral fellowship at the McGill Cancer Centre.